Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.292. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: NCI P30 CA051008
National Institutes of Health
Grant: NCI P50CA101942
Bristol-Myers Squibb
Grant: N/A
NCI NIH HHS
Grant: P50 CA101942
NCI NIH HHS
Grant: P30 CA051008
NCATS NIH HHS
Grant: UL1 TR001863
National Institutes of Health
Grant: 3P30CA051008-16S1
CANCER CENTER SUPPORT GRANT
National Institutes of Health
Grant: 2P50CA101942-11A1
DF/HCC Kidney Cancer SPORE
FWCI
1.94
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals